Development and progression of chronic kidney disease (CKD) in patients with renal cell carcinoma (RCC) after radical nephrectomy remains an extremely pressing contemporary issue.
Postoperative changes of the ultrasound resistance index (RI) in the contralateral kidney not affected by the tumor after surgical treatment of RCC, as well as correlations between changes in IR and in glomerular filtration rate (GFR) remain far from being comprehensively investigated.
The RI changes in the parenchyma of the intact (unaffected by the tumor) kidney before and after surgical treatment for RCC, and establishing correlations between RI changes and creatinine-dependent GFR remain unexplored issues.
Objective. To assess the correlation between RI and GFR in the kidney not affected by the RCC before and after radical nephrectomy.

Materials and methods. The study enrolled 49 patients. Group I included 37 patients with an initial diagnosis of RCC (on the right), Stage III of the disease, and without signs of chronic renal failure (GFR was ≥ 90 ml/min/1.73 m2).
In patients with RCC, six months after surgery, the RI increase in the contralateral kidney unaffected by the tumor was significantly associated with a significant reduction in GFR. Thus, RI can be potentially used to predict the development of CKD in this patient population.

Purpose: Prostate cancer (PCa) is the second most common cancer in men. The urge to guide treatment tactics based on personal clinical risk factors has evolved in the era of human genome sequencing. To date, personalized approaches to managing PCa patients have not yet been developed. Radiogenomics is a relatively new term, used to refer to the study of genetic variation associated with imaging features of the tumour in order to improve the prognostication of the disease course.
Material and methods: The study is a review of recent knowledge regarding potential clinical applications of radiogenomics in personalized treatment of PCa.
Results: Recent investigations have proven that by combining data on individual genetic tumour features, and radiomic profiling (radiologic-molecular correlation), with traditional staging procedures in order to personalize treatment of PCa, an improved prognostication of PCa course can be performed, and overtreatment of indolent cancer can be avoided. It was found that a combination of multiparametric MRI and gene expression data allowed the detection of radiomic features of PCa, which correlated with a number of gene signatures associated with adverse outcomes.
It was revealed that several molecular markers may drive tumour upstaging, allowed the distinction between the PCa
stages, and correlated with aggressiveness-related radiomic features.
Conclusions: The radiogenomics of PCa is not a comprehensively investigated area of oncourology. The combination
of genomics and radiomics as integrative parts of precision medicine in the future has the potential to become the
foundation for a personalized approach to the management of PCa.